Rights and permissions
About this article
Cite this article
Perindopril “very likely is cost-effective” for CAD in Europe. Pharmacoecon. Outcomes News 491, 7 (2005). https://doi.org/10.2165/00151234-200504910-00014
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200504910-00014